investora2z Wednesday, 11/27/13 11:03:07 AM Re: None Post # of 2727 The reaction to the merger is positive, and the volumes are also good. This is part of the strategic transition announced by Biozone some time back. More details about benefits of the merger with Cocrystal Discovery will emerge over the next few days and weeks. The combined company will initially continue to trade on the OTCBB under the existing symbol of BZNE. The existing shareholders of Biozone and Cocrystal will own approximately 40% and 60% of the combined company respectively, and the merger is expected to close at the end of the year. Cocrystal Discovery is a biotechnology company developing antiviral therapeutics for human diseases. Frost Group and his companies Teva (TEVA) & OPKO (OPK) have earlier made investments in Corcrystal. The PR mentions that the company has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza, the Human Rhinovirus (HRV), Dengue, and the Norovirus. It is targeting two Hepatitis C replication enzymes, with its Polymerase program at lead optimization stage and its Helicase program is at lead identification stage. Dr. Gary Wilcox, the existing CEO and Chairman of Cocrystal, will be the CEO and Chairman of the combined entity. Wilcox expects that the merger will significantly enhance Cocrystal's ability to bring its small molecule inhibitors of the viral replication complex to market. Dr. Frost also expressed confidence about the future of the combined entity due to the quality of the management. Dr. Wilcox has a good track record in the industry. He has served on the Board of Icos Corporation for several years during which Icos was sold to Eli Lilly for $2.3 billion. At Icos, he led the teams which developed Cialis which now has annual sales of $2 billion. Noble Prize winner Dr. Roger Kornberg, Chief Scientist and a Director of Cocrystal Discovery, will be the Chief Scientist of the combined entity.